Incannex completes Phase 2 enrollment in RePOSA trial of IHL-42X for OSA; topline data expected H1 2025

Incannex Healthcare Inc.

Completed enrollment of >120 patients across 11 U.S. sites in Phase 2 dose-finding portion of RePOSA Phase 2/3 study of IHL-42X for OSA.
Topline Phase 2 clinical data expected in first half 2025; results will determine optimal dose for Phase 3.
Phase 3 expansion planned with ~440 patients across four treatment arms over 52 weeks to support future FDA NDA submission.
IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide targeting physiological pathways of OSA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.